|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EXOSC7 |
Gene summary for EXOSC7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EXOSC7 | Gene ID | 23016 |
| Gene name | exosome component 7 | |
| Gene Alias | EAP1 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0000288 | UniProtAcc | A0A024R2P7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23016 | EXOSC7 | LZE3D | Human | Esophagus | HGIN | 3.44e-02 | 4.01e-01 | 0.0668 |
| 23016 | EXOSC7 | LZE4T | Human | Esophagus | ESCC | 4.79e-11 | 3.62e-01 | 0.0811 |
| 23016 | EXOSC7 | LZE7T | Human | Esophagus | ESCC | 1.47e-05 | 4.22e-01 | 0.0667 |
| 23016 | EXOSC7 | LZE24T | Human | Esophagus | ESCC | 2.41e-04 | 3.28e-01 | 0.0596 |
| 23016 | EXOSC7 | LZE6T | Human | Esophagus | ESCC | 5.54e-05 | 8.21e-02 | 0.0845 |
| 23016 | EXOSC7 | P1T-E | Human | Esophagus | ESCC | 4.99e-05 | 3.41e-01 | 0.0875 |
| 23016 | EXOSC7 | P2T-E | Human | Esophagus | ESCC | 3.28e-21 | 3.56e-01 | 0.1177 |
| 23016 | EXOSC7 | P4T-E | Human | Esophagus | ESCC | 1.04e-24 | 8.60e-01 | 0.1323 |
| 23016 | EXOSC7 | P5T-E | Human | Esophagus | ESCC | 3.91e-21 | 4.07e-01 | 0.1327 |
| 23016 | EXOSC7 | P8T-E | Human | Esophagus | ESCC | 1.23e-24 | 1.81e-01 | 0.0889 |
| 23016 | EXOSC7 | P9T-E | Human | Esophagus | ESCC | 2.97e-10 | 2.29e-01 | 0.1131 |
| 23016 | EXOSC7 | P10T-E | Human | Esophagus | ESCC | 1.48e-27 | 4.03e-01 | 0.116 |
| 23016 | EXOSC7 | P11T-E | Human | Esophagus | ESCC | 8.32e-08 | 2.69e-01 | 0.1426 |
| 23016 | EXOSC7 | P12T-E | Human | Esophagus | ESCC | 5.55e-46 | 9.09e-01 | 0.1122 |
| 23016 | EXOSC7 | P15T-E | Human | Esophagus | ESCC | 5.60e-15 | 4.07e-01 | 0.1149 |
| 23016 | EXOSC7 | P16T-E | Human | Esophagus | ESCC | 4.68e-31 | 4.14e-01 | 0.1153 |
| 23016 | EXOSC7 | P17T-E | Human | Esophagus | ESCC | 1.00e-05 | 3.51e-01 | 0.1278 |
| 23016 | EXOSC7 | P19T-E | Human | Esophagus | ESCC | 3.68e-03 | 4.39e-01 | 0.1662 |
| 23016 | EXOSC7 | P20T-E | Human | Esophagus | ESCC | 8.44e-20 | 3.49e-01 | 0.1124 |
| 23016 | EXOSC7 | P21T-E | Human | Esophagus | ESCC | 9.90e-31 | 5.69e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
| GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
| GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
| GO:1903311110 | Esophagus | ESCC | regulation of mRNA metabolic process | 210/8552 | 288/18723 | 3.25e-21 | 5.56e-19 | 210 |
| GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
| GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
| GO:0006402110 | Esophagus | ESCC | mRNA catabolic process | 170/8552 | 232/18723 | 8.70e-18 | 8.00e-16 | 170 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
| GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
| GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
| GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
| GO:000095618 | Esophagus | ESCC | nuclear-transcribed mRNA catabolic process | 88/8552 | 112/18723 | 9.41e-13 | 4.14e-11 | 88 |
| GO:00905013 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:190331316 | Esophagus | ESCC | positive regulation of mRNA metabolic process | 87/8552 | 118/18723 | 5.10e-10 | 1.32e-08 | 87 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa03018 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
| hsa030181 | Liver | Cirrhotic | RNA degradation | 44/2530 | 79/8465 | 1.43e-06 | 1.65e-05 | 1.02e-05 | 44 |
| hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301823 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
| hsa0301833 | Oral cavity | LP | RNA degradation | 39/2418 | 79/8465 | 6.98e-05 | 4.38e-04 | 2.83e-04 | 39 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EXOSC7 | SNV | Missense_Mutation | rs774989692 | c.58N>A | p.Glu20Lys | p.E20K | Q15024 | protein_coding | tolerated(0.13) | benign(0.001) | TCGA-D8-A1JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
| EXOSC7 | insertion | Nonsense_Mutation | novel | c.405_406insACACACTGACAAATCCAGGTCACAGTGCTGGTCTGGTTCATTACA | p.Leu135_Tyr136insThrHisTerGlnIleGlnValThrValLeuValTrpPheIleThr | p.L135_Y136insTH*QIQVTVLVWFIT | Q15024 | protein_coding | TCGA-AO-A0JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophospamide | SD | ||
| EXOSC7 | SNV | Missense_Mutation | rs140459270 | c.407N>G | p.Tyr136Cys | p.Y136C | Q15024 | protein_coding | deleterious(0.01) | possibly_damaging(0.558) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EXOSC7 | SNV | Missense_Mutation | rs774516290 | c.442N>G | p.Leu148Val | p.L148V | Q15024 | protein_coding | deleterious(0.01) | benign(0.12) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EXOSC7 | SNV | Missense_Mutation | c.371N>G | p.Leu124Arg | p.L124R | Q15024 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| EXOSC7 | SNV | Missense_Mutation | rs770116250 | c.530C>T | p.Ser177Leu | p.S177L | Q15024 | protein_coding | tolerated(0.26) | benign(0.011) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EXOSC7 | SNV | Missense_Mutation | novel | c.670N>A | p.Ala224Thr | p.A224T | Q15024 | protein_coding | deleterious(0.01) | possibly_damaging(0.463) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| EXOSC7 | SNV | Missense_Mutation | c.581N>C | p.Val194Ala | p.V194A | Q15024 | protein_coding | tolerated(0.06) | benign(0.025) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| EXOSC7 | SNV | Missense_Mutation | c.243N>A | p.Phe81Leu | p.F81L | Q15024 | protein_coding | deleterious(0.01) | possibly_damaging(0.56) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| EXOSC7 | SNV | Missense_Mutation | c.98N>T | p.Arg33Leu | p.R33L | Q15024 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |